Maxim Group upgraded Co-Diagnostics (NASDAQ:CODX) to “buy” from “hold” with a $30 price target, saying that COVID-19 testing has been transformative for the company. The stock closed at $18.85 on May 19. Co-Diagnostics...
HalioDx, a closely-held immuno-oncology diagnostic company, signed a collaboration with ImCheck Therapeutics to generate tumor immune contexture information for patients enrolled in EVICTION, the first-in-human clinical...
BTIG downgraded Endologix (NASDAQ:ELGX) to “neutral” without a price target, citing “greater uncertainty” that the potential COVID-19 impact on revenue could put the company’s financial covenants in peril. The stock...
SVB Leerink launched coverage of Compugen (NASDAQ:CGEN) with an “outperform” rating and $15 price target. The stock closed at $13.22 on May 6. “TIGIT / PVRIG could be the next evolution in immune checkpoint blockade...
Janney Montgomery Scott initiated coverage of Y-mAbs Therapeutics (NASDAQ:YMAB) with a “buy” rating and fair value estimate of $45. The stock closed at $35.03 on April 30. Y-mAbs is developing immunotherapies for...
Ladenburg Thalmann launched coverage of Salarius Pharmaceuticals (NASDAQ:SLRX) with a “buy” rating and price target of $3.80. The stock closed at 63 cents on April 24. Salarius obtained a NASDAQ listing through a...
Mesoblast (NASDAQ:MESO; ASX:MSB) reported an 83% survival in 10-of-12, or 83%, of ventilator-dependent COVID-19 patients with moderate/severe acute respiratory distress syndrome (ARDS) treated during March-April 2020...
Brookline Capital Markets initiated coverage of Bellerophon Therapeutics (NASDAQ:BLPH) with a “buy” rating and $35 price target. The stock closed at $11.91 on April 13. Bellerophon is developing inhaled nitric oxide...
Health Canada approved Spartan Bioscience’s DNA analyzer, the Spartan Cube, as a rapid, accurate and portable COVID-19 test. Closely-held Spartan plans to immediately begin shipping the test to its federal and...
Cowen launched coverage of Stereotaxis (NYSE American:STXS) with an “outperform” rating and $6 price target. The stock closed at $2.71 on April 8. Genesis is Stereotaxis’ next-generation robotic magnetic navigation...